Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8505765 | Veterinary Microbiology | 2016 | 8 Pages |
Abstract
Rift Valley fever virus (RVFV), a Category A pathogen and select agent, is the causative agent of Rift Valley fever. To date, no fully licensed vaccine is available in the U.S. for human or animal use and effective antiviral drugs have not been identified. The RVFV MP12 strain is conditionally licensed for use for veterinary purposes in the U.S. which was excluded from the select agent rule of Health and Human Services and the U.S. Department of Agriculture. The MP12 vaccine strain is commonly used in BSL-2 laboratories that is generally not virulent in mice. To establish a small animal model that can be used in a BSL-2 facility for antiviral drug development, we investigated susceptibility of six mouse strains (129S6/SvEv, STAT-1 KO, 129S1/SvlmJ, C57BL/6J, NZW/LacJ, BALB/c) to the MP12 virus infection via an intranasal inoculation route. Severe weight loss, obvious clinical and neurologic signs, and 50% mortality was observed in the STAT-1 KO mice, whereas the other 5 mouse strains did not display obvious and/or severe disease. Virus replication and histopathological lesions were detected in brain and liver of MP12-infected STAT-1 KO mice that developed the acute-onset hepatitis and delayed-onset encephalitis. In conclusion, the STAT-1 KO mouse strain is susceptible to MP12 virus infection, indicating that it can be used to investigate RVFV antivirals in a BSL-2 environment.
Keywords
Related Topics
Life Sciences
Agricultural and Biological Sciences
Animal Science and Zoology
Authors
Yuekun Lang, Jamie Henningson, Dane Jasperson, Yonghai Li, Jinhwa Lee, Jingjiao Ma, Yuhao Li, Nan Cao, Haixia Liu, William Wilson, Juergen Richt, Mark Ruder, Scott McVey, Wenjun PhD,